FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading
Company Releases Early Clinical Data For Experimental Blood Cancer Drug
<a href="https://pixabay.com/users/SarahMarciano/">SarahMarciano</a> / Pixabay

Company Releases Early Clinical Data For Experimental Blood Cancer Drug

According to a story from pm360online.com, the biopharmaceutical company miRagen Therapeutics, Inc., recently presented Phase I clinical trial data regarding the company's experimental drug cobomarsen. This data was presented at…

Continue Reading
Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders
<a href="https://pixabay.com/users/PublicDomainPictures/">PublicDomainPictures</a> / Pixabay

Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders

According to a story from PR Newswire, presentations at the 60th annual American Society of Hematology Meeting and Exposition are highlighting the results of four large scale clinical trials that…

Continue Reading
Close Menu